Delcath Systems announces publication of subgroup analyses of phase 3 FOCUS study of Melphalan/Hepatic Delivery System in patients with unresectable metastatic uveal melanoma Queensbury, New York ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback